Mostrar el registro sencillo del ítem
dc.contributor.author
Otero-losada, Matilde Estela
dc.contributor.author
Petrovsky, Nikolai
dc.contributor.author
Alami, Abdallah
dc.contributor.author
Crispo, James
dc.contributor.author
Mattison, Donald
dc.contributor.author
Capani, Francisco
dc.contributor.author
Goetz, Christopher
dc.contributor.author
Krewski, Daniel
dc.contributor.author
Perez Lloret, Santiago
dc.date.available
2024-01-03T14:25:48Z
dc.date.issued
2022-09
dc.identifier.citation
Otero-losada, Matilde Estela; Petrovsky, Nikolai; Alami, Abdallah; Crispo, James; Mattison, Donald; et al.; Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom; Taylor & Francis; Expert Opinion On Drug Safety; 22; 4; 9-2022; 343-349
dc.identifier.issn
1474-0338
dc.identifier.uri
http://hdl.handle.net/11336/222236
dc.description.abstract
Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30), postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia (1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53, 1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29–0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety (0.75 (0.67–0.85). Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Taylor & Francis
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
BNT162B2
dc.subject
CHADOX1
dc.subject
COVID-19
dc.subject
NEUROLOGY
dc.subject
PHARMACOVIGILANCE
dc.subject
PSYCHIATRY
dc.subject
SAFETY
dc.subject
VACCINES
dc.subject.classification
Psiquiatría
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-01-02T11:45:45Z
dc.journal.volume
22
dc.journal.number
4
dc.journal.pagination
343-349
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Otero-losada, Matilde Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires; Argentina
dc.description.fil
Fil: Petrovsky, Nikolai. Flinders University.; Australia
dc.description.fil
Fil: Alami, Abdallah. University of Ottawa; Canadá
dc.description.fil
Fil: Crispo, James. Carleton University; Canadá. University of British Columbia; Canadá
dc.description.fil
Fil: Mattison, Donald. University of Ottawa; Canadá. University of South Carolina; Chile
dc.description.fil
Fil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires; Argentina. Universidad Autónoma de Chile; Chile
dc.description.fil
Fil: Goetz, Christopher. Rush University Medical Center (rumc);
dc.description.fil
Fil: Krewski, Daniel. University of Ottawa; Canadá
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
dc.journal.title
Expert Opinion On Drug Safety
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14740338.2022.2120607
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14740338.2022.2120607
Archivos asociados